Receptor tyrosine kinase structure and function in mammalian health and disease

he study of receptor tyrosine kinases has been of fundamental biological interest with implications for treating a wide range of ailments including cancer, diabetes and atherosclerosis. Our understanding of such biology has led to the discovery and use of therapeutics, including small molecule inhibitors and humanised antibodies that have been approved for treatment of cancer and ocular disease. Our expanding knowledge of receptor tyrosine kinases has identified a myriad of functions, with implications for treating many ailments. By considering past and current advances in the field, this meeting aims to look towards a new and coherent understanding of receptor function and how this can be utilised for therapeutic gain.



Topics:

ErbB function in epithelial physiology
Insulin and insulin-like growth factor receptor function
VEGF, Angiopoietin and Ephrins control of vascular physiology and disease
Trk regulation of neuronal function
Emerging receptor tyrosine kinase models in health and disease
Strategies for discovering new therapeutics that target receptor tyrosine kinases

+ show speakers and program

Sunday 1 September 2013
15:00 - 16:20 Registration
16:20 - 16:30 Welcome and Introduction
16:30 - 17:30
Disruptions on the highways of cell signalling
Dario Alessi (University of Dundee, United Kingdom)
17:30 - 18:30 Drinks Reception
18:30 - 20:00 Dinner
Epithelial RTK biology


Monday 2 September 2013
09:00 - 09:40
Activation and inhibition of ErbB family RTKs
Mark Lemmon (University of Pennsylvania School of Medicine, U.S.A.)
09:40 - 10:00
Selected Oral Communication
10:00 - 10:40
EGF receptor endocytosis: mechanisms and role in signalling
Alexander Sorkin (University of Pittsburgh, U.S.A.)
10:40 - 11:00 Coffee/tea break
11:00 - 11:40
EGF receptor trafficking and signalling
Michael Clague (University of Liverpool, United Kingdom)
11:40 - 12:00
Selected Oral Communication
12:00 - 12:40
Clare Futter (University College London, United Kingdom)
12:40 - 14:00 Lunch
RTK signalling and disease


Monday 2 September 2013
14:00 - 14:40
Nicholas Tonks (Cold Spring Harbor Laboratory, U.S.A.)
14:40 - 15:00
Selected Oral Communication
15:00 - 15:40
Biasing IGF-1R Signaling through G-protein coupled receptors (GPCR). Therapeutic implications for cancer treatment
Leonard Girnita (Karolinska Institutet, Sweden)
15:40 - 16:00 Coffee/tea break
16:00 - 16:40
Mark Kearney (University of Leeds, United Kingdom)
16:40 - 17:00
Selected Oral Communication
17:00 - 17:40
Control mechanisms of FGFR activity
John Ladbury (M D Anderson Cancer Center, U.S.A.)
18:00 - 19:00 Dinner
19:00 - 21:00 Drinks Reception with Poster Session
21:00 - 23:00 Ceilidh
RTK function in vascular physiology


Tuesday 3 September 2013
09:00 - 09:40
Combining chemistry and cell biology to target VEGFR regulation of vascular physiology
Sreenivasan Ponnambalam (University of Leeds, United Kingdom)
09:40 - 10:00
Selected Oral Communication
10:00 - 10:40
Bala Ambati (University of Utah, U.S.A.)
10:40 - 11:00
Selected Oral Communication
11:00 - 11:20 Coffee/tea break
11:20 - 12:00
Stopping and starting of cell migrations - the role of Eph receptors during cancer invasion and wound healing
Catherine Nobes (University of Bristol, United Kingdom)
12:00 - 12:20
Selected Oral Communication
12:20 - 13:00
Probing structure and mechanism of the receptor tyrosine kinase Tie2
Nicholas Brindle (University of Leicester, United Kingdom)
13:00 - 14:00 Lunch
14:00 - 18:00 Free time or excursion
18:00 - 19:00 Dinner
19:00 - 21:00 Drinks Reception with Poster Session
RTK function in neurophysiology


Wednesday 4 September 2013
09:00 - 09:40
Sortilin receptors are critical regulators of receptor tyrosine kinase activity in psychiatric disorders and diabetes
Anders Nykjaer (Aarhus University, Denmark)
09:40 - 10:00
Selected Oral Communication
10:00 - 10:40
Catching signal dynamics surfing the net
Boris Kholodenko (University College Dublin, Ireland)
10:40 - 11:00 Coffee/tea break
11:00 - 11:40
The role of Wnt5a/Ryk signaling in cortical axon outgrowth and guidance
Katherine Kalil (University of Wisconsin-Madison, U.S.A.)
11:40 - 12:00
Selected Oral Communication
12:00 - 12:40
Giampietro Schiavo (CRUK London Research Institute, United Kingdom)
12:40 - 14:00 Lunch
Emerging RTK targets in cancer therapy


Wednesday 4 September 2013
14:00 - 14:40
VEGFR antagonists as cancer therapeutics
Simon Barry (AstraZeneca, United Kingdom)
14:40 - 15:00
Selected Oral Communication
15:00 - 15:40
Anaplastic Lymphoma Kinase in human cancer
Bengt Hallberg (UmeƄ University, Sweden)
15:40 - 16:00 Coffee/tea break
16:00 - 16:40
Architecture and regulation of the RET receptor tyrosine kinase
Neil McDonald (London Research Institute, United Kingdom)
17:00 - 18:00
Joseph Schlessinger (Yale University, U.S.A.)
18:00 - 19:30 Dinner
19:30 Drinks Reception

1 Sep - 3 Sep 2013
Sheffield
United Kingdom
meeting website